SCM
NKTR icon

Stonepine Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Stonepine Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.42M Buy
120,654
+35,654
+42% +$2.61M 4.75% 4
2026
Q1 		$6.12M Hold
85,000
– – 2.45% 9
2025
Q4 		$3.59M Hold
85,000
– – 2.62% 7
2025
Q3 		$4.84M Buy
85,000
+34,800
+69% +$1.15M 3.93% 5
2025
Q2 		$1.3M Buy
+50,200
New +$564K 1.27% 20
2024
Q2 		– Sell
-232,027
Closed -$3.25M – 28
2024
Q1 		$3.25M Buy
+232,027
New +$2.43M 2.58% 8

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stonepine Capital Management's NKTR Position: Q2 2026 in Review

Stonepine Capital Management increased its Nektar Therapeutics (NKTR) stake by 42% in Q2 2026, buying an estimated $2.61M and bringing the position to 120,654 shares worth $8.42M. The position accounts for 4.75% of the portfolio, ranked #4.

Stonepine Capital Management first reported a position in NKTR in Q1 2024 and has held it in 6 quarters since. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Stonepine Capital Management held 120,654 shares of Nektar Therapeutics worth $8.42M as of Q2 2026.
  • Stonepine Capital Management bought 35,654 Nektar Therapeutics shares in Q2 2026, an estimated $2.61M.
  • Nektar Therapeutics made up 4.75% of Stonepine Capital Management's portfolio in Q2 2026, its #4 holding.
  • Stonepine Capital Management first reported a position in Nektar Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.